跳到主要內容區塊
:::

周楠華 Nan-Haw Chow

Nan-Haw,Chow 

周楠華 病理科 教授(Nan-Haw Chow)

E-mail:chownh@mail.ncku.edu.tw

電話:06-2353535 分機5288

傳真:06-2766195

 

學經歷

 

學歷
 

臺大醫學院病理研究所碩士

    中國醫藥學院醫學系
   

 

現職   成大醫學院病理學科教授
     
 
 

經歷

2001-迄 成大醫學院病理學科教授

 

1997-1998 約翰霍普金斯大學, Brady 泌尿中心研究員

 

1996-2001 成大醫學院病理學科副教授

 

1989-1996 成大醫學院病理學科講師

 

1983-1986 臺大醫學院病理學科助教

 

專長/研究興趣

 

腫瘤病理學、腫瘤生物學、實驗診斷學
   

 

興趣:

  1. 建立膀胱癌致癌的基因模式:
    臺灣南部地區, 膀胱癌不論在發生率、死亡率方面均明顯地高於平均值。我們針對一些常見致癌基因(proto-oncogenes) (1,2,4-6,8,9)及抑癌基因(tumor suppressor genes) (6,10)進行一系列的臨床及基礎研究,已建立了膀胱癌致癌的基因模式 (圖一)。利用微小衛星體 (microsatellite) 定位的分子遺傳研究裏,我們也建立了一個參與膀胱癌惡化 (progression) 的染色體變化模式 (3,7) (圖二)。 在人類基因計劃的基因序列資料公佈之後,未來希望能找尋新的重要基因,幫助癌症的早期診斷,有效的治療以及準確的預後指標找尋(3)

  2. 建立癌症的化學預防模式及血管新生致病機轉研究:
    經過多年的基因表現藍圖 (gene expression profiling) 篩選、生物資訊分析和分子腫瘤學的研究,我們已找到一些膀胱癌新穎致癌基因及重要受體型酪胺酸激酶 (receptor tyrosine kinase, RTK)如表皮生長因子受體 (EGFR)、c-Met、RON、PDGFR、和Axl等 (1,4,5,8,9)、以及血管新生相關的標靶 (6)。同時也發現這些基因參與致癌的分子機轉: 如細胞基質的互動、生長因子受體的交叉對話 (cross-talk)(1,2, 4,5)、對抗壓力或缺氧的能力(2) (圖三)等。為了進一步改善現今化療的癌症治療成效,減少毒性和抗藥性的問題,我們將朝向發展高特異性、低毒性的標靶治療,最終目的是希望提高癌症的治療成效

 

榮譽獎項

 

 

 
 

研究成果 (Publications) -- Nan-Haw Chow

 
  1. Wang YW, Li WM, Wu WJ, Chai CY, Chang TY, Sun Y, Cheng CJ, Shiue YL, Su SJ, Cheng HL, Liu HS, Chow NH. Epithelial membrane protein 2 is a prognostic indicator for patients with urothelial carcinoma of the upper urinary tract. Am J Pathol 183: 709-19, 2013.

  2. Yeh CY, Shin SM, Yeh HH, Wu TJ, Shin JW, Chang TY, Giri R, Lee CT, Chiang JH, Tseng SM, Lee YC, Shen CH, Chow NH(Co-coresponding author), Liu HS: Transcriptional activation of the Axl and PDGFR-alpha by c-Met through a ras- and Src-independent mechanism in human bladder cancer. BMC Cancer 11:139, 2011. (Highly accessed)

  3. Liu HS, Hsu PY, Lai MD, Chang HY, Ho CL, Cheng HL, Chen HT, Lin YJ, Wu TJ, Tzai TS, Chow NH: An unusual function of RON receptor tyrosine kinase as a transcriptional regulator in cooperation with EGFR in human cancer cells. Carcinogenesis 31: 1456-1564. 2010.

  4. Ho CL, Tzai TS, Chen JC, Tsai HW, Cheng HL, Eisenberger CF, Chow NH: The molecular signature for urothelial carcinoma of the upper urinary tract. J Urol 179: 1155-1159, 2008. 

  5. Hsu PY, Liu HS, Ho CL, Cheng HL, Tzai TS, Chang TY, Guo HR, Chow NH: Collaboration of RON and EGFR in human bladder carcinogenesis. J Urol 176(5): 2262-2267, 2006.

  6. Cheng HL, Liu HS, Lin YJ, Chen HW, Hsu PY, Chang TY, Ho CL, Tzai TS, Chow NH: Co-expression of RON and MET is a prognostic indicator for patients with transitional cell carcinoma of the bladder. Br J Cancer 9(10) 1906-1914, 2005.

  7. Su SJ, Yeh TM, Chuang WJ, Ho CL, Chang KL, Cheng HL, Liu HS, Cheng HL, Hsu PY, Chow NH: The Novel Targets for Anti-angiogenesis of Genistein on Human Cancer Cells. Biochem Pharmacol 69: 307-318, 2005.

  8. Tzai TS, Tsai YS, Chow NH: The prevalence and clinicopathologic correlate of p16INK4, Retinoblastoma, and p53 immunoreactivity in locally advanced urinary bladder cancer. Urol Oncol 22(2):112-118, 2004.

  9. Tzai TSi, Chen HW, Chan SH, Ho CL, Tsai YS, Cheng HL, Dai YC, Lin SN, Yang WH, Chow NH: Clinical significance of allelotype profiling for urothelial carcinoma. Urology 62: 378-384, 2003.

  10. Cheng HL, Trink B, Tzai TS, Liu HS, Chan SH, Ho CL, Sidransky D, Chow NH: Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder. A comparison with p53 nuclear accumulation. J Clin Oncol 20(60): 1544-1550, 2002.

  11. Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS: Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 2001 7:1957-1962, 2001.

  12. Su SJ, Lai MD, Yeh TM, Chow NH: Overexpression of HER-2/neu enhances sensitivity of human bladder cancer cells to urinary isoflavones. Eu J Cancer 37:1413-1418, 2001.

  13. Huang SM, Lee JC, Wu TJ, Chow NH: Clinical relevance of vascular endothelial growth factor for thyroid neoplasms. World J Surg 25: 302-306,2001.

  14. Lee JC, Lin YJ, Chow NH, Wang ST: Reappraisal of the role of NM23-H1 in colorectal cancers. J Surg Oncol 76: 58-62, 2001.

  15. Cheng HL, Tong YC, Tzai TS, Weng CL, Ho CL, Yang WH, Lin Jonny SN, Chow NH: Expression of nm23-H1 in transitional cell carcinoma of the upper urinary tract. Oncol Rep, 8: 193-196, 2001.

  16. Chow NH, Cairns P, Eisenberger CF, Schoenberg MP, Taylor DC, Epstein JI, Sidransky D: Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. Int J Cancer 89(6): 514-518, 2000.

  17. Chow NH, Liu HS, Chan SH: The role of nm23-H1 in the progression of transitional cell bladder cancer. Clin Cancer Res 6(3): 3595-3599, 2000.

  18. Su SJ, Yeh TM, Lei HY, Chow NH: The potential of soybean foods as a chemoprevention approach for human urinary tract cancer. Clin Cancer Res 6(1): 230-236, 2000.

  19. Chow NH, Tzai TS, Cheng HL, Liu HS, Chan SH, Tong YC: The clinical value of p21WAF1/CIP1 expression in superficial bladder cancer. Anticancer Res 20(1): 1173-1176, 2000.

  20. Eisenberger CF, Schoenberg M, Enger C, Hortopan S, Shah S, Chow NH, Marshall FF, Sidransky D: Diagnosis of renal cancer by molecular urinalysis. J Natl Cancer Inst 91 (23): 2028-2032, 1999.

  21. Docimo SG., Chow NH, Steiner G,. Silver RI, Rodriguez R, Kinsman S, Sidransky D: Schoenberg M. Detection of adenocarcinoma by urinary microsatellite analysis after augmentation cystoplasty. Urology 54(3):561, 1999.

  22. Chow NH, Liu HS, Chan SH, Cheng HL, Tzai TS: Expression of vascular endothelial growth factor in primary superficial bladder cancer. Anticancer Res 19 (5C): 4593-4598, 1999.

  23. Eisenberger CF, Walsh PC, Eisenberger MA, Chow NH, Partin AW, Mostwin JL, Marshall FF, Epstein JI, Schoenberg MP: Incidental non-Hodgkin's lymphoma in patients with localized prostate cancer. Urology 53(1): 175-179, 1999.

  24. Chow NH, Cheng CJ, Chi YC, Liu HS, Tzai TS, Lin JSN: Potential value of urinary intercellular adhesion molecule-1 determination in patients with bladder cancer. Urology 52(6): 1015-1019, 1998.

  25. Baker LA, Chow NH, Docimo SG, Gearhart JP, Sidransky D, Schoenberg MP: Microsatellite deoxyribonucleic acid analysis to detect bladder cancer in bladder extrophy. J Urol 160 (6 Pt 1): 2192-2193, 1998.

  26. Tzai TS, Chow NH, Lin JSN, Yang WH, Tong YC: The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role on the outcome of postoperative intravesical chemotherapy. Anticancer Res 18 (6B): 4717-4722, 1998.

  27. Tzai TS, Shiau AL, Wu CL, Chow NH, Tsai YS: Modulating antitumor immunity of MBT-2 murine bladder tumor bearing mice by postoperative administration of interferon-α. Anticancer Res 18 (5A): 3355-3362, 1998.

  28. Chow NH, Liu HS, Chang CJ, Chi YC, Tzai TS, Li IC, Lin JSN: Urinary excretion of transforming growth factor-alpha in patients with transitional cell carcinoma. Anticancer Res 18 (3B): 2053-2058, 1998.

  29. Chow NH, Guo YL, Lin SN, Su HJ, Tzai TS, Guo HR, Su IJ: Clinicopathologic features of bladder cancer associated with chronic exposure to arsenic. Br J Cancer 75(11): 1708-1710, 1997.

  30. Cheng HL, Chow NH, Tzai TS, Tong YC, Lin SN, Chan SH, Yang WH, Chang CC, Lin YM: Prognostic significance of proliferating cell nuclear antigen expression in transitional cell carcinoma of the upper urinary tract. Anticancer Res 17(4A): 2789-2794, 1997.

  31. Chow NH, Liu HS, Yang HB, Chan SH, Su IJ: Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma. An immunohistochemical study. Virchows Archiv 430(6): 461-466, 1997.

  32. Chow NH, Liu HS, Lee IC, Chang CJ, Chan SH, Cheng HL, Tzai TS, Lin SN: Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res 172B: 1293-1296, 1997.

  33. Tzai TS, Lin SN, Chow NH: Modulation of the antitumor immunity of tumor bearing mice with low-dose cyclophosphamide. J Surg Res 65(2): 139-144, 1996.

  34. Lee SH, Lin SN, Tzai TS, Chow NH, Tong YC, Yang WH, Chang CC, Cheng HL: Prognostic factors of primary transitional cell carcinoma of the upper urinary tract. Eur Urol 29(3): 266-271, 1996

  35. Chow NH, Chang CJ, Yeh TM, Chan SH, Tzai TS, Lin SN: Implications of urinary basic fibroblast growth factor excretion in patients with urothelial carcinoma. Clin Sci 90(2): 127-133, 1996.

  36. Chow NH, Chang CJ, Cheng PE, Tzai TS, Huang CM, Lin SN: Clinical significance of urinary ferritin excretion in patients with transitional cell carcinoma. Clin Sci 88(6): 701-6, 1995.

  37. Chow NH, Tzai TS, Cheng PE, Chang CJ, Lin SN, Tang MJ: An assessment of immunoreactive epidermal growth factor in urine of patients with urological diseases. Urol Res 22 (4): 221- 5, 1994.

  38. Chow NH, Tzai TS, Lin SN, Su WC, Cheng HL: Near-diploid transitional cell carcinoma: a preliminary report. Int Urol Nephrol 26(4): 423-30, 1994.

  39. Chow NH, Tzai TS, Cheng HL, Chan SH, Lin SN: Urinary cytodiagnosis. Can it have a different prognostic implication than a diagnostic test? Urol Int 53(1): 18-23, 1994.

  40. Tzai TS, Lin SN, Chow NH: Effects of chemoimmunotherapy with and without surgery in murine MBT-2 bladder tumor. Urol Int 53(1): 6-11, 1994.

  41. Lee SE, Chow NH, Chi YC, Tzai TS, Yang WH, Lin SH: Expression of c-erbB-2 protein in normal and neoplastic urothelium: Lack of adverse prognostic effect in human urinary bladder cancer. Anticancer Res 14(3B): 1317-24, 1994.

  42. Chow NH, Tzai TS, Lin SN,Chan SH,Tang MJ: Reappraisal of the biological role of epidermal growth factor receptor (EGFR) in transitional cell carcinoma. Eur Urol 24 (1): 140-3, 1993.

 

 
實驗室
 
  研究生王怡文(博士班)、江承堯(博士班)、 張鴻議(博士班)、丁雅柔(碩士班)

 

實驗室花絮

 

 

 

 

瀏覽數:
加到我的最愛